Why Vir Biotechnology’s tobevibart and elebsiran combo may signal a breakthrough in hepatitis delta treatment

Vir Biotechnology, Inc. (Nasdaq: VIR) has released encouraging new data from its Phase 2 SOLSTICE trial, showing that the combination of tobevibart and elebsiran achieved a 66 percent rate of undetectable hepatitis delta virus (HDV) RNA at 48 weeks in patients with chronic hepatitis delta. The results were presented during the 2025 American Association for the Study of Liver Diseases (AASLD) Liver Meeting held in Washington, D.C., and were simultaneously published in the New England Journal of Medicine, underscoring the growing significance of the program in the infectious disease landscape.

The readout marks a milestone in Vir Biotechnology’s strategy to advance new therapies for viral hepatitis, a category still underserved by existing treatment options. The company is now progressing to late-stage trials under the ECLIPSE registrational program, with topline data expected by the first quarter of 2027. If these trends hold, the dual therapy could become one of the first approved treatments for hepatitis delta in the United States and potentially reshape the treatment standard globally.

What do the SOLSTICE Phase 2 results reveal about viral suppression in chronic hepatitis delta?

The Phase 2 SOLSTICE trial evaluated the efficacy and safety of a once-monthly subcutaneous regimen combining tobevibart, a monoclonal antibody, and elebsiran, an RNA interference (RNAi) agent. Among the 32 participants with chronic hepatitis delta, 66 percent achieved sustained HDV RNA target not detected (TND) status by Week 48. The results are particularly significant given the inclusion of patients with cirrhosis and high baseline viral loads, which typically complicate treatment response.

Alanine aminotransferase (ALT) normalization was achieved in 56 percent of participants, indicating improvements in liver inflammation. Furthermore, approximately 90 percent of patients achieved a reduction in hepatitis B surface antigen (HBsAg) to levels below 10 IU/mL. Since hepatitis delta virus requires HBsAg for replication, the observed HBsAg suppression suggests a biological mechanism that may directly impair HDV persistence.

From a safety perspective, the therapy demonstrated a favorable profile. There were no treatment-related Grade 3 or higher adverse events, and no participants discontinued treatment due to side effects. Most adverse events were described as mild or moderate and transient in nature, strengthening the case for broader clinical use.

Why is HDV such a challenging target—and what makes this therapy different?

Chronic hepatitis delta is regarded as the most severe form of viral hepatitis. It is caused by co-infection with hepatitis B virus (HBV) and hepatitis delta virus and has been recently classified as carcinogenic by the International Agency for Research on Cancer. Patients with chronic hepatitis delta often experience rapid progression to cirrhosis, liver failure, and liver-related mortality. Despite its severity, there are no therapies approved for HDV in the United States, and global treatment options remain limited.

The combination of tobevibart and elebsiran represents a novel dual-mechanism approach. Tobevibart is a broadly neutralizing monoclonal antibody developed by Vir Biotechnology that targets HBsAg. It is designed to block viral entry into liver cells and reduce circulating viral particles. Tobevibart includes Xtend technology licensed from Xencor, Inc., which extends the half-life of the drug for sustained immune engagement. Elebsiran, on the other hand, is a small interfering RNA (siRNA) agent developed by Alnylam Pharmaceuticals, Inc. It is designed to degrade HBV RNA transcripts, reducing HBsAg production and further inhibiting HDV replication.

This dual action approach, combining entry inhibition with gene silencing, gives the therapy a broader mechanism than currently available treatments such as bulevirtide, which is approved in the European Union but still not authorized in the United States. The monthly dosing regimen further adds to patient convenience, with potential benefits in long-term adherence and clinical outcomes.

How is the ECLIPSE program structured and what is its regulatory trajectory?

The ECLIPSE program includes three randomized, controlled clinical trials designed to serve as the registrational backbone for global regulatory submissions. ECLIPSE 1 is a Phase 3 trial evaluating tobevibart and elebsiran against deferred treatment, particularly in regions where bulevirtide is not routinely used. ECLIPSE 2 is also a Phase 3 trial focused on patients who have previously received bulevirtide but failed to achieve viral suppression. ECLIPSE 3 is a Phase 2b head-to-head comparison between the combination therapy and bulevirtide in patients who are treatment-naïve.

Vir Biotechnology has confirmed that ECLIPSE 1 has already completed enrollment, ahead of schedule. Topline data from all three trials is expected in the first quarter of 2027. The program has also received multiple regulatory designations that may accelerate development timelines. In the United States, the combination has been granted Breakthrough Therapy and Fast Track designations by the Food and Drug Administration. In Europe, the therapy holds Priority Medicines (PRIME) and orphan drug designations from the European Medicines Agency.

Marianne De Backer, Chief Executive Officer of Vir Biotechnology, emphasized that the new data validated the company’s strategic commitment to addressing unmet needs in liver disease. She noted that the publication of SOLSTICE results in the New England Journal of Medicine reinforced the scientific and clinical rigor of the program and pointed to the potential of a monthly, well-tolerated regimen to improve patient outcomes.

How are institutional investors and market analysts interpreting the SOLSTICE results in the context of Vir Biotechnology’s long-term valuation outlook?

Investor sentiment surrounding Vir Biotechnology has remained cautious throughout 2025, reflecting general volatility in the biotechnology sector and post-pandemic repricing of infectious disease assets. The company’s shares have experienced fluctuations tied to news flow from its infectious disease and oncology programs, with attention gradually returning to the hepatitis delta franchise following the SOLSTICE announcement.

While analysts have not issued unified forward guidance, there is a growing consensus that the dual therapy’s mechanism, safety profile, and convenient dosing could position it as a first-in-class treatment in the United States if ECLIPSE results match or exceed SOLSTICE outcomes. The key question for analysts now centers around long-term durability and scalability, particularly as the drug candidate nears its commercial evaluation phase.

Some institutional investors have also noted the broader licensing and platform model employed by Vir Biotechnology, which allows it to combine internally developed monoclonal antibodies with licensed RNAi technologies, expanding the company’s innovation pipeline without overextending development resources.

How does this program align with Vir Biotechnology’s broader strategic direction?

The hepatitis delta combination therapy fits squarely within Vir Biotechnology’s mission of using immune system-based strategies to tackle serious infectious diseases. Beyond tobevibart and elebsiran, the American biotechnology firm is advancing a pipeline of dual-masked T-cell engagers for solid tumors and preclinical candidates across multiple infectious disease indications.

Tobevibart, developed in-house, reflects Vir Biotechnology’s expertise in antibody discovery and immune modulation. Its extended half-life and immune clearance enhancements are part of a broader push to make antibody therapies more durable and clinically effective. Elebsiran complements this approach by leveraging Alnylam Pharmaceuticals’ RNAi platform, which is already validated in rare disease indications and now being applied to chronic viral infections.

The partnership-driven development model is emerging as a viable template for mid-cap biotechnology firms seeking to maximize clinical output while managing cost and regulatory complexity. In this context, the SOLSTICE results not only represent progress for hepatitis delta patients but also serve as a proof point for Vir Biotechnology’s collaborative innovation strategy.

Can 2027 mark the beginning of a new era in hepatitis delta treatment?

With no approved therapies currently available in the United States and limited options globally, the burden of chronic hepatitis delta continues to challenge clinicians and patients alike. The 66 percent response rate demonstrated in the SOLSTICE Phase 2 trial provides an early but compelling signal that the combination of tobevibart and elebsiran may fill a major treatment gap.

As the ECLIPSE trials move toward final readouts, the key questions will revolve around scalability, durability, and real-world applicability of the therapy. If those hurdles are cleared, Vir Biotechnology may find itself at the center of one of the most important therapeutic advances in liver disease in over a decade.

Key takeaways from Vir Biotechnology’s SOLSTICE trial update on hepatitis delta treatment

• Vir Biotechnology’s tobevibart and elebsiran combination achieved undetectable HDV RNA in 66 percent of patients at Week 48
• 90 percent of patients showed HBsAg reduction to <10 IU/mL, with 56 percent achieving ALT normalization
• No treatment-related Grade 3 or higher adverse events or discontinuations were observed
• Data were presented at the 2025 AASLD Liver Meeting and published in the New England Journal of Medicine
• The ECLIPSE registrational program includes three global trials, with topline results expected in Q1 2027
• The therapy has received Breakthrough Therapy, Fast Track (FDA), and PRIME, orphan (EMA) designations
• Institutional sentiment is cautiously optimistic ahead of 2027 readouts, with attention on the dual mechanism and monthly dosing model